CNS Drugs

, Volume 27, Issue 2, pp 113–119 | Cite as

Sudden Unexpected Death in Epilepsy

Potential Role of Antiepileptic Drugs
Review Article


Among people with epilepsy, there is a 20-fold higher risk of dying suddenly and unexpectedly compared with the general population. This phenomenon is called sudden unexpected death in epilepsy (SUDEP) and the term is used when sudden death occurs in an otherwise reasonably healthy person with epilepsy and the autopsy is unrevealing. In most cases, SUDEP occurs during sleep and is unwitnessed. Risk factors for SUDEP include the presence or number of generalized tonic–clonic seizures (GTCS), nocturnal seizures, young age at epilepsy onset, longer duration of epilepsy, dementia, absence of cerebrovascular disease, asthma, male gender, symptomatic aetiology of epilepsy and alcohol abuse. Suggested factors predisposing to SUDEP have included long-QT-related mutations, impaired serotonergic brain stem control of respiration, altered autonomic control and seizures with a pronounced postictal suppression and respiratory compromise. Final events that may lead up to SUDEP are a postictal CNS shutdown with pronounced EEG suppression, ictal or postictal apnoea, and ictal cardiac arrhythmia. It is unknown whether antiepileptic drugs (AEDs) modify the risk for SUDEP. Studies have consistently found that the presence or number of GTCS is associated with an increased risk for SUDEP. Since continued presence of GTCS clearly necessitates the use of AEDs, both factors must be taken into account to determine whether one or both increases the risk for SUDEP. Some studies suggest that AEDs, such as lamotrigine and carbamazepine, may increase the risk of SUDEP, but rarely adjust for GTCS. Other studies, which have found that AEDs are associated with a decreased SUDEP risk, either adjust for the number of GTCS or are meta-analyses of randomized clinical trials. Studies assessing the impact of AEDs on the risk for SUDEP are limited because SUDEP is a rare event, making randomized clinical trials impossible to conduct. Observational studies focus on whether or not an AED was prescribed. When postmortem AED concentrations are assessed they are usually low or absent, perhaps due to sampling in deceased individuals, making it difficult to fully resolve whether AEDs increase or decrease SUDEP risk. Despite these caveats, the evidence suggests that AEDs are not associated with an increased risk for SUDEP on a population level, although some individuals may be susceptible to effects of AEDs. Recent evidence from a meta-analysis of randomized clinical trials of adjunctive AEDs at efficacious doses provides strong support for AED treatment as mono- or polytherapy to increase seizure control and protect against SUDEP in patients with refractory epilepsy. For patients for whom seizure control is unattainable, supervision or monitoring may prevent SUDEP, though this has never been formally tested.



This effort was unfunded. Dr. Hesdorffer participated in an advisory board in which mortality was discussed. Dr. Tomson served as a consultant for GSK in a blinded adjudication of SUDEP events.


  1. 1.
    Ficker DM, So EL, Annegers JF, et al. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology. 1998;51(5):1270–4.PubMedCrossRefGoogle Scholar
  2. 2.
    Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected death in epilepsy. Epilepsia. 2012;53(2):227–33.PubMedCrossRefGoogle Scholar
  3. 3.
    Langan Y, Nashef L, Sander JW. Sudden unexpected death in epilepsy: a series of witnessed deaths. J Neurol Neurosurg Psychiatry. 2000;68(2):211–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol. 2008;7(11):1021–31.PubMedCrossRefGoogle Scholar
  5. 5.
    Sillanpää M, Shinnar S. Long-term mortality in childhood-onset epilepsy. N Engl J Med. 2010;363(26):2522–9.PubMedCrossRefGoogle Scholar
  6. 6.
    First Seizure Trial Group (FIRST Group). Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic clonic seizure. Neurology 1993;43(3):478–483.Google Scholar
  7. 7.
    Marson A, Jacoby A, Johnson A, on behalf of the Medical Research Council MESS Study Group, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomized controlled trial. Lancet. 2005;365(9476):2007–13.PubMedCrossRefGoogle Scholar
  8. 8.
    Hesdorffer DC, Tomson T, Benn E, for the ILAE Commission on Epidemiology (Subcommission on Mortality), et al. Do antiepileptic drugs or generalized tonic-clonic seizure frequency increase SUDEP risk? A combined analysis. Epilepsia. 2012;53(2):249–52.PubMedCrossRefGoogle Scholar
  9. 9.
    Aurlien D, Larsen JP, Gjerstad L, Taubøll E. Increased risk of sudden unexpected death in epilepsy in females using lamotrigine: a nested, case-control study. Epilepsia. 2012;53(2):258–66.PubMedCrossRefGoogle Scholar
  10. 10.
    Nilsson L, Farahmand BY, Persson PG, et al. Risk factors for sudden unexpected death in epilepsy: a case-control study. Lancet. 1999;353(9156):888–93.PubMedCrossRefGoogle Scholar
  11. 11.
    Walczak TS, Leppik IE, D’Amelio M, et al. Incidence and risk factors in sudden unexpected death in epilepsy: a prospective cohort study. Neurology. 2001;56(4):519–25.PubMedCrossRefGoogle Scholar
  12. 12.
    Langan Y, Nashef L, Sander JW. Case-control study of SUDEP. Neurology. 2005;64(7):1131–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Hitiris N, Suratman S, Kelly K, et al. Sudden unexpected death in epilepsy: a search for risk factors. Epilepsy Behav. 2007;10(1):138–41.PubMedCrossRefGoogle Scholar
  14. 14.
    Hesdorffer DC, Tomson T, Benn E, for the ILAE Commission on Epidemiology (Subcommission on Mortality), et al. Combined analysis of risk factors for SUDEP. Epilepsia. 2011;52(6):1150–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Lamberts RJ, Thijs RD, Laffan A, et al. Sudden unexpected death in epilepsy: people with nocturnal seizures may be at highest risk. Epilepsia. 2012;53(2):253–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Jick SS, Cole TB, Mesher RA, et al. Sudden unexpected death in young persons with primary epilepsy. Pharmacoepidemiol Drug Safety. 1992;1(2):59–64.CrossRefGoogle Scholar
  17. 17.
    Nilsson L, Bergman U, Diwan VK, et al. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: a case–control study. Epilepsia. 2001;42(5):667–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents, and their prevention. Epilepsy Res. 2004;60(1):1–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Berg AT, Shinnar S, Levy FM, et al. Two-year remission and subsequent relapse in children with newly diagnosed epilepsy. Epilepsia. 2001;42(12):1553–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Tu E, Bagnall RD, Duflou J, Semsarian C. Post-mortem review and genetic analysis of sudden unexpected death in epilepsy (SUDEP) cases. Brain Pathol. 2011;21(2):201–8.PubMedCrossRefGoogle Scholar
  21. 21.
    Tupal S, Faingold CL. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia. 2005;47(1):21–6.CrossRefGoogle Scholar
  22. 22.
    Surges R, Thijs RD, Tan HL, Sander JW. Sudden unexpected death in epilepsy: risk factors and potential pathomechanisms. Nat Rev Neurol. 2009;5(9):492–504.PubMedCrossRefGoogle Scholar
  23. 23.
    Lhatoo SD, Faulkner HJ, Dembny K, et al. An electroclinical case-control study of sudden unexpected death in epilepsy. Ann Neurol. 2010;68(6):787–96.PubMedCrossRefGoogle Scholar
  24. 24.
    So EL, Sam MC, Lagerlund TL. Postictal central apnea as a cause of SUDEP: evidence from near-SUDEP incident. Epilepsia. 2000;41(11):1494–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Espinosa PS, Lee JW, Tedrow UB, Bromfield EB, Dworetzky BA. Sudden unexpected near death in epilepsy: malignant arrhythmia from a partial seizure. Neurology. 2009;72(19):1702–3.PubMedCrossRefGoogle Scholar
  26. 26.
    Aurlien D, Leren TP, Taubøll E, Gjerstad. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure. 2009;18(2):158–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Cantwell R, Clutton-Brock T, Cooper G, on behalf of the Centre for Maternal and Child Enquiries, et al. Saving mother’s lives: reviewing maternal deaths to make motherhood safer: 2006–2008. Br J Obstet Gyn. 2001;118(Suppl. 1):1–205.Google Scholar
  28. 28.
    Danielsson BR, Lansdell K, Patmore L, Tomson T. Effects of the antiepileptic drugs lamotrigine, topiramate and gabapentin on hERG potassium currents. Epilepsy Res. 2005;63(1):17–25.PubMedCrossRefGoogle Scholar
  29. 29.
    Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology. 2002;59(2):251–5.PubMedCrossRefGoogle Scholar
  30. 30.
    Ohman I, Beck O, Vitols S, Tomson T. Plasma concentrations of lamotrigine and its 2-N-glucuronide metabolite during pregnancy in women with epilepsy. Epilepsia. 2008;49(6):1075–80.PubMedCrossRefGoogle Scholar
  31. 31.
    Herzog AG, Blum AS, Farina EL, et al. Valproate and lamotrigine level variation with menstrual cycle phase and oral contraceptive use. Neurology. 2009;72(10):911–4.PubMedCrossRefGoogle Scholar
  32. 32.
    Tomson T, Kennebäck G. Arrhythmia, heart rate variability, and antiepileptic drugs. Epilepsia. 1997;38(Suppl. 11):S48–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Persson H, Ericson M, Tomson T. Carbamazepine affects autonomic cardiac control in patients with newly diagnosed epilepsy. Epilepsy Res. 2003;57(1):69–75.PubMedCrossRefGoogle Scholar
  34. 34.
    Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomized trials. Lancet Neurol. 2011;10(11):961–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM study. Neurology. 2008;71(20):1572–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Ridsdale L, Charlton J, Ashworth M, et al. Epilepsy mortality and risk factors for death in epilepsy: a population-based study. Br J Gen Pract. 2011;61(586):e271–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Terrence CF Jr, Wisotzkey HM, Perper JA. Unexpected, unexplained death in epileptic patients. Neurology. 1975;25(6):594–8.PubMedCrossRefGoogle Scholar
  38. 38.
    George JR, Davis GG. Comparison of anti-epileptic drug levels in different cases of sudden death. J Forensic Sci. 1998;43(3):598–603.PubMedGoogle Scholar
  39. 39.
    Leestma JE, Kalelkar MB, Teas SS, et al. Sudden unexpected death associated with seizures: analysis of 66 cases. Epilepsia. 1984;25(1):84–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Leestma JE, Walczak T, Hughes JR, et al. A prospective study on sudden unexpected death in epilepsy. Ann Neurol. 1989;26(2):195–203.PubMedCrossRefGoogle Scholar
  41. 41.
    Lear-Kaul KC, Coughlin L, Dobersen MJ. Sudden unexpected death in epilepsy, a retrospective study. Am J Forensic Med Pathol. 2005;26(1):11–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Kloster R, Engelskjon T. Sudden unexpected death in epilepsy: a clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry. 1999;67(4):439–44.PubMedCrossRefGoogle Scholar
  43. 43.
    Opeskin K, Burke MP, Cordner SM, Berkovic SF. Comparison of antiepileptic drug levels in sudden unexpected death in epilepsy with death from other causes. Epilepsia. 1999;40(12):1795–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Tomson T, Skold AC, Holmgen P, et al. Postmortem changes in blood concentrations of phenytoin and carbamazepine: an experimental study. Ther Drug Monit. 1998;20(3):309–12.PubMedCrossRefGoogle Scholar
  45. 45.
    Williams J, Lawthom C, Dunstan FD, et al. Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy. J Neurol Neurosurg Psychiatry. 2006;77(4):481–4.PubMedCrossRefGoogle Scholar
  46. 46.
    Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3(4):338–42.PubMedCrossRefGoogle Scholar
  47. 47.
    Kennebäck G, Ericson M, Tomson T, Bergfeldt L. Changes in arrhythmia profile and heart rate variability during abrupt withdrawal of antiepileptic drugs: implications for sudden death. Seizure. 1997;6:369–75.PubMedCrossRefGoogle Scholar
  48. 48.
    Hennessy MJ, Tighe MG, Binnie CD, Nashef L. Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep. Neurology. 2001;57:1650–4.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  1. 1.Gertrude H. Sergievsky Center and Department of EpidemiologyColumbia UniversityNew YorkUSA
  2. 2.Department of Clinical NeuroscienceKarolinska InstituteStockholmSweden

Personalised recommendations